Please ensure Javascript is enabled for purposes of website accessibility

Why Horizon Therapeutics Is Soaring Today

By Prosper Junior Bakiny – May 6, 2020 at 12:39PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors were impressed with the company’s first-quarter financial results.

What happened? 

Shares of Horizon Therapeutics (HZNP 3.83%) are up by 16% as of 12:03 p.m. EDT on Wednesday following the company's release of its first-quarter earnings report. Investors were impressed with Horizon's quarterly update, with the company's revenue and earnings coming in much higher than analyst estimates.

So what

During the first quarter, Horizon's net sales were $355.9 million, representing a 27% year-over-year increase. On average, analysts expected the company to record net sales of $287.9 million. Also, Horizon's non-GAAP (adjusted) net income for the quarter was $83.2 million -- or $0.40 on a per-share basis -- compared to the non-GAAP net income of $53.9 million and non-GAAP EPS of $0.30 the company recorded during the prior-year quarter. Horizon's $0.40 non-GAAP EPS was significantly higher than the $0.22 analysts had been expecting. 

Stacked wooden blocks with upward arrows drawn on them.

Image source: Getty Images.

Horizon's strong performance during the first quarter was driven by several of its key products. For instance, the company's gout treatment Krystexxa had sales of $93.3 million, representing a 78% increase compared to the year-ago period. Further, Horizon's Ravicti -- which helps prevent a buildup of ammonia in the blood -- had sales of $61.2 million, up 23% year over year. Lastly, Tepezza, a treatment for thyroid eye disease (TED) that was approved in January, had sales of $23.5 million during the first quarter.

Now what

In its quarterly update, Horizon said that Tepezza "exceeded" its expectations during the first quarter. The success of this new product is one of the main factors behind Horizon's decision to revise its guidance upward for the current fiscal year. The pharma company had previously announced that it expected its net sales for the year to be between $1.40 billion and $1.42 billion. Now Horizon expects its net sales for 2020 to be between $1.40 billion and $1.45 billion.

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Horizon Therapeutics Public Limited Company Stock Quote
Horizon Therapeutics Public Limited Company
HZNP
$64.26 (3.83%) $2.37

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.